Excel Diagnostics and Nuclear Oncology Center (EDNOC), a diagnostic imaging and radioligand therapy center in Houston, Texas announced the approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration Resistant Prostate Cancer (mCRPC).
To
read more please visit:
Source: RadioMedix